<DOC>
	<DOCNO>NCT00700570</DOCNO>
	<brief_summary>This single arm study assess resection rate liver metastasis , time disease progression , safety neoadjuvant treatment Avastin combination oxaliplatin capecitabine ( XELOX ) patient metastatic colorectal cancer unresectable liver metastasis . Patients receive Avastin 5mg/kg iv day 1 every 2 week cycle , oxaliplatin 85mg/m2 iv day 1 every 2 week cycle , capecitabine 1000mg/m2 day 1-5 8-12 every 2 week cycle . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With XELOX Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>adult patient , &lt; =75 year age ; chemotherapynaive stage IV colorectal cancer unresectable liver metastasis ; &gt; =1 measurable lesion ; ECOG status 02. prior exposure Avastin ; clinical radiological evidence CNS metastases ; uncontrolled hypertension , clinically significant cardiovascular disease ; ongoing treatment aspirin ( &gt; 325mg/day ) medication know predispose gastrointestinal ulceration .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>